Beheshti Mohsen, Heinzel Alexander, von Mallek Dirk, Filss Christian, Mottaghy Felix M
Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, Germany -
Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University, Salzburg, Austria -
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):29-36. doi: 10.23736/S1824-4785.19.03155-8. Epub 2019 Jan 15.
Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics, clinical performance, safety and toxicity of PSMA targeted β- or α-radiation therapy.
在晚期转移性去势抵抗性前列腺癌（mCRPC）患者中确定最佳治疗方法在常规临床实践中仍然具有挑战性。近年来，使用β或α发射体如177-镥（177Lu）或225-锕（225Ac）进行前列腺特异性膜抗原（PSMA）靶向放射性核素治疗一直是多个学术研究中心的主要关注点。本文综述了PSMA的特性、PSMA靶向β或α放射治疗的临床疗效、安全性和毒性。
